Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer

Justin M. Drake, John K. Lee, Owen N. Witte

Research output: Contribution to journalArticlepeer-review

75 Scopus citations


Clinical therapies for cancer have evolved from toxic, nontargeted agents to manageable, highly targeted therapies. Protein tyrosine kinases are a family of signaling molecules implicated in nearly every cancer type and are the foundation for the development of modern targeted agents. Recent genomic analyses have identified activating mutations, translocations, and amplifications of tyrosine kinases. Selective targeting of these genetically altered tyrosine kinases has resulted in significant clinical advances, including increased patient survival. This indicates that altered protein tyrosine kinases are the main drivers of many different cancers. However, lost during analyses of genetic lesions are the contributions of activated, wild-type kinases on tumordependent pathways. New approaches in phosphoproteomic technologies have identified several wild-type tyrosine kinase activation states, suggesting that non-genetically altered kinases can be essential "nodes" for signal transduction. Here, we summarize the evidence supporting the common mechanisms of protein tyrosine kinase activation in cancer and provide a personal perspective on the kinases BCR-ABL and BTK, as well as nonmutated kinase targets in prostate cancer, through our work. We outline the mechanisms of tyrosine kinase activation in the absence of direct mutation and discuss whether non-genetically altered tyrosine kinases or their associated downstream signaling pathways can be effectively targeted.

Original languageEnglish (US)
Pages (from-to)1722-1732
Number of pages11
JournalMolecular and cellular biology
Issue number10
StatePublished - May 2014


Dive into the research topics of 'Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer'. Together they form a unique fingerprint.

Cite this